Access and Evidence
Comprehensive strategies for market access
Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers.
More Access and Evidence Articles
Access and Evidence
Market access: Risk sharing and alternative pricing schemes
Shared-risk agreements can represent uncertain rewards for drug makers and
payers. What you need to know before entering into one.
Access and Evidence
Market access and patient access schemes
Leela Barham explores the potential for patient access schemes (PAS) to help
companies achieve market access.
Access and Evidence
Market access: How to get REMS right
Andrew Tolve reports on ways to make the most of Risk Evaluation and
Management Strategies.
Access and Evidence
Market access: China and international reference pricing
Cyrus Chowdhury explores the impact on market access if China adopts a
pricing scheme referencing India, South Korea, and the Philippines.
Access and Evidence
Market access: How to meet both marketing authorisation and HTA needs
Leela Barham looks at the costs and benefits of taking a more collaborative
approach towards marketing authorisation and Health Technology Assessments.
Access and Evidence
Is value-based pricing an aid to market access?
Leela Barham explores whether pharma firms can use value-based pricing (VBP)
to improve market access.
Access and Evidence
Market access: figuring out the FDA
Seeking approval from the US Food and Drug Administration can be complex and
painfully slow. Alan Minsk offers tips to make the process simpler, quicker,
and more efficient.
Access and Evidence
Pharma 3.0: what it means for market access
Peter Mansell explores the new partnerships and new models needed to assure
successful market access strategies.
Access and Evidence
Market access: the importance of understanding payers
Marcus Deans explains the necessity of knowing why and how payers make
decisions.